DKK1 and prostate cancer: Silencing of DKK-1 delayed the development of bone lesions in a model of prostate cancer[26], and neutralizing DKK-1 antibodies have been successfully applied to prevent bone lesions in a preclinical model of myeloma bone disease[13].